BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36300564)

  • 1. Identifying the location of locoregional recurrences after definitive radiotherapy for head and neck cancer using metabolic parameters of baseline and mid-treatment 18F-FDG-PET scans.
    Aren E; Trada Y; Lee M; Deshpande S; Jameson MG; Johnston M; Berry M; Estall V; Fowler A
    J Med Imaging Radiat Oncol; 2023 Feb; 67(1):89-97. PubMed ID: 36300564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrences after intensity modulated radiotherapy for head and neck squamous cell carcinoma more likely to originate from regions with high baseline [18F]-FDG uptake.
    Due AK; Vogelius IR; Aznar MC; Bentzen SM; Berthelsen AK; Korreman SS; Loft A; Kristensen CA; Specht L
    Radiother Oncol; 2014 Jun; 111(3):360-5. PubMed ID: 24993331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns-of-failure guided biological target volume definition for head and neck cancer patients: FDG-PET and dosimetric analysis of dose escalation candidate subregions.
    Mohamed ASR; Cardenas CE; Garden AS; Awan MJ; Rock CD; Westergaard SA; Brandon Gunn G; Belal AM; El-Gowily AG; Lai SY; Rosenthal DI; Fuller CD; Aristophanous M
    Radiother Oncol; 2017 Aug; 124(2):248-255. PubMed ID: 28774596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of [
    Pisani C; Vigna L; Mastroleo F; Loi G; Amisano V; Masini L; Deantonio L; Aluffi Valletti P; Sacchetti G; Krengli M
    Radiat Oncol; 2021 Mar; 16(1):57. PubMed ID: 33743759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.
    Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R
    Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reproducibility of FDG PET based metabolic tumor volume measurements and of their FDG distribution within.
    Kruse V; Mees G; Maes A; D'Asseler Y; Borms M; Cocquyt V; Van De Wiele C
    Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):462-8. PubMed ID: 24695005
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    van den Bosch S; Doornaert PAH; Dijkema T; Zwijnenburg EM; Verhoef LCG; Hoeben BAW; Kasperts N; Smid EJ; Terhaard CHJ; Kaanders JHAM
    Radiother Oncol; 2020 Jan; 142():107-114. PubMed ID: 31439447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary tumor delineation based on (18)FDG PET for locally advanced head and neck cancer treated by chemo-radiotherapy.
    Leclerc M; Lartigau E; Lacornerie T; Daisne JF; Kramar A; Grégoire V
    Radiother Oncol; 2015 Jul; 116(1):87-93. PubMed ID: 26088157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiparametric functional MRI and
    Martens RM; Koopman T; Lavini C; Ali M; Peeters CFW; Noij DP; Zwezerijnen G; Marcus JT; Vergeer MR; Leemans CR; de Bree R; de Graaf P; Boellaard R; Castelijns JA
    Eur Radiol; 2021 Feb; 31(2):616-628. PubMed ID: 32851444
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Kim SA; Roh JL; Kim JS; Lee JH; Lee SH; Choi SH; Nam SY; Kim SY
    Eur J Cancer; 2017 Feb; 72():62-70. PubMed ID: 28027517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic Accuracy of
    Murtojärvi S; Malaspina S; Kinnunen I; Tuokkola T; Honka MJ; Saunavaara V; Tolvanen T; Schrey A; Kemppainen J
    Contrast Media Mol Imaging; 2022; 2022():8676787. PubMed ID: 36082064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDG-PET/contrast-enhanced CT as a post-treatment tool in head and neck squamous cell carcinoma: comparison with FDG-PET/non-contrast-enhanced CT and contrast-enhanced CT.
    Suenaga Y; Kitajima K; Ishihara T; Sasaki R; Otsuki N; Nibu K; Minamikawa T; Kiyota N; Sugimura K
    Eur Radiol; 2016 Apr; 26(4):1018-30. PubMed ID: 26188656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Diffusion-Weighted Imaging and
    Noij DP; Martens RM; Koopman T; Hoekstra OS; Comans EFI; Zwezerijnen B; de Bree R; de Graaf P; Castelijns JA
    Clin Oncol (R Coll Radiol); 2018 Dec; 30(12):780-792. PubMed ID: 30318343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of tumour region of interest delineation method for mid-treatment FDG-PET response prediction in head and neck squamous cell carcinoma undergoing radiotherapy.
    Trada Y; Lin P; Lee MT; Jameson MG; Chlap P; Keall P; Moses D; Fowler A
    Quant Imaging Med Surg; 2023 May; 13(5):2822-2836. PubMed ID: 37179931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive 18fluoro-2-deoxyglucose positron emission tomography/computed tomography-based target volume delineation in radiotherapy planning of head and neck cancer.
    Moule RN; Kayani I; Prior T; Lemon C; Goodchild K; Sanghera B; Wong WL; Saunders MI
    Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):364-71. PubMed ID: 21109410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.
    Anderson CM; Chang T; Graham MM; Marquardt MD; Button A; Smith BJ; Menda Y; Sun W; Pagedar NA; Buatti JM
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):472-9. PubMed ID: 25680593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1-[11C]-acetate PET imaging in head and neck cancer--a comparison with 18F-FDG-PET: implications for staging and radiotherapy planning.
    Sun A; Sörensen J; Karlsson M; Turesson I; Langström B; Nilsson P; Cederblad L; Bertling J; Riklund K; Johansson S
    Eur J Nucl Med Mol Imaging; 2007 May; 34(5):651-657. PubMed ID: 17146654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging of tumour hypoxia and metabolism in patients with head and neck squamous cell carcinoma.
    Zegers CM; van Elmpt W; Hoebers FJ; Troost EG; Öllers MC; Mottaghy FM; Lambin P
    Acta Oncol; 2015; 54(9):1378-84. PubMed ID: 26213313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic Performance of Response Assessment FDG-PET/CECT in HNSCC Treated With Definitive Radio(chemo)therapy Using NI-RADS.
    Paul S; Gupta T; Purandare N; Joshi K; Ghosh-Laskar S; Budrukkar A; Swain M; Sinha S; Kumar A; Joshi A; Prabhash K; Nair S; Rangarajan V; Agarwal JP
    Otolaryngol Head Neck Surg; 2023 Oct; 169(4):938-947. PubMed ID: 36856038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-FDG versus 11C-choline PET/CT for the imaging of advanced head and neck cancer after combined intra-arterial chemotherapy and radiotherapy: the time period during which PET/CT can reliably detect non-recurrence.
    Ito K; Yokoyama J; Kubota K; Morooka M; Shiibashi M; Matsuda H
    Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1318-27. PubMed ID: 20306040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.